through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili
Company profile
Ticker
BIIB
Exchange
Website
CEO
George Scangos
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BIOGEN IDEC INC, BIOGEN IDEC INC., IDEC PHARMACEUTICALS CORP / CA, IDEC PHARMACEUTICALS CORP / DE
SEC CIK
Corporate docs
Subsidiaries
Biogen Foundation Inc. • Biogen MA Inc. • Biogen Realty Corporation • Biogen Realty Limited Partnership • Biogen U.S. Corporation • Biogen U.S. Limited Partnership • BDH U.S. Holdco Inc. • Biogen (RTP) Realty LLC • Biogen Chesapeake LLC • Biogen Digital Health Inc. ...
IRS number
330112644
BIIB stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
12 Apr 24
10-K
2023 FY
Annual report
13 Feb 24
8-K
Biogen reports fourth quarter and full year 2023 results and expects return to Non-GAAP EPS growth in 2024
13 Feb 24
8-K
Amendments to Articles of Incorporation or Bylaws
12 Dec 23
8-K
Departure of Directors or Certain Officers
8 Nov 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Biogen reports third quarter 2023 results and updates full year 2023 guidance
8 Nov 23
8-K/A
Submission of Matters to a Vote of Security Holders
28 Sep 23
8-K
Biogen Completes Acquisition of Reata Pharmaceuticals
26 Sep 23
8-K
Entry into a Material Definitive Agreement
1 Sep 23
Transcripts
BIIB
Earnings call transcript
2023 Q4
13 Feb 24
BIIB
Earnings call transcript
2023 Q3
8 Nov 23
BIIB
Earnings call transcript
2023 Q2
25 Jul 23
BIIB
Earnings call transcript
2023 Q1
25 Apr 23
BIIB
Earnings call transcript
2022 Q4
15 Feb 23
BIIB
Earnings call transcript
2022 Q3
25 Oct 22
BIIB
Earnings call transcript
2022 Q2
20 Jul 22
BIIB
Earnings call transcript
2022 Q1
3 May 22
BIIB
Earnings call transcript
2021 Q4
3 Feb 22
BIIB
Earnings call transcript
2021 Q3
20 Oct 21
Latest ownership filings
4
Priya Singhal
3 Apr 24
4
Nicole Murphy
3 Apr 24
144
Notice of proposed sale of securities
2 Apr 24
4
Priya Singhal
26 Feb 24
144
Notice of proposed sale of securities
22 Feb 24
4
SUSAN H ALEXANDER
21 Feb 24
4
Ginger Gregory
21 Feb 24
4
Rachid Izzar
21 Feb 24
4
Robin Kramer
21 Feb 24
4
MICHAEL R MCDONNELL
21 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.29 bn | 2.29 bn | 2.29 bn | 2.29 bn | 2.29 bn | 2.29 bn |
Cash burn (monthly) | 109.97 mm | 115.64 mm | 47.07 mm | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 734.23 mm | 772.12 mm | 314.26 mm | n/a | n/a | n/a |
Cash remaining | 1.55 bn | 1.52 bn | 1.97 bn | n/a | n/a | n/a |
Runway (months of cash) | 14.1 | 13.1 | 41.9 | n/a | n/a | n/a |
Institutional ownership, Q4 2023
64.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 792 |
Opened positions | 103 |
Closed positions | 236 |
Increased positions | 220 |
Reduced positions | 296 |
13F shares | Current |
---|---|
Total value | 22.36 tn |
Total shares | 93.92 mm |
Total puts | 551.26 k |
Total calls | 586.94 k |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
Primecap Management | 16.26 mm | $4.21 tn |
Vanguard | 14.41 mm | $3.73 tn |
STT State Street | 6.95 mm | $1.80 tn |
Wellington Management | 5.32 mm | $1.38 tn |
JPM JPMorgan Chase & Co. | 5.01 mm | $1.30 tn |
IVZ Invesco | 1.81 mm | $469.58 bn |
Clearbridge Advisors | 1.68 mm | $434.55 bn |
MS Morgan Stanley | 1.58 mm | $408.28 bn |
LGEN Legal & General | 1.57 mm | $405.69 bn |
T. Rowe Price | 1.51 mm | $390.32 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Apr 24 | Priya Singhal | Common Stock | Sell | Dispose S | No | No | 213.09 | 93 | 19.82 k | 4,886.476 |
1 Apr 24 | Nicole Murphy | Common Stock | Payment of exercise | Dispose F | No | No | 214.83 | 117 | 25.14 k | 9,634.374 |
1 Apr 24 | Nicole Murphy | Common Stock | Option exercise | Acquire M | No | No | 0 | 240 | 0.00 | 9,751.374 |
1 Apr 24 | Nicole Murphy | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 240 | 0.00 | 0 |
22 Feb 24 | Priya Singhal | Common Stock | Sell | Dispose S | No | No | 221.23 | 262 | 57.96 k | 4,886.092 |
16 Feb 24 | Priya Singhal | Common Stock | Sell | Dispose S | No | No | 221.49 | 108 | 23.92 k | 5,148.092 |
16 Feb 24 | Priya Singhal | Common Stock | Payment of exercise | Dispose F | No | No | 219.08 | 173 | 37.90 k | 5,256.092 |
16 Feb 24 | Priya Singhal | Common Stock | Option exercise | Acquire M | No | No | 0 | 389 | 0.00 | 5,429.092 |
16 Feb 24 | Priya Singhal | Common Stock | Payment of exercise | Dispose F | No | No | 219.08 | 295 | 64.63 k | 5,040.092 |
16 Feb 24 | Priya Singhal | Common Stock | Option exercise | Acquire M | No | No | 0 | 819 | 0.00 | 5,335.092 |
News
Wedbush Maintains Neutral on Biogen, Lowers Price Target to $213
17 Apr 24
B of A Securities Maintains Neutral on Biogen, Lowers Price Target to $260
12 Apr 24
Where Biogen Stands With Analysts
11 Apr 24
JP Morgan Maintains Neutral on Biogen, Lowers Price Target to $240
11 Apr 24
10 Health Care Stocks With Whale Alerts In Today's Session
9 Apr 24
Press releases
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
31 Mar 24
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
21 Mar 24
Anixa Biosciences (NASDAQ:ANIX) Gains Attention for Its Innovative Cancer Therapies Amid Biopharma Sector Growth
20 Mar 24
Anixa Biosciences (NASDAQ:ANIX) Gains Attention for Its Innovative Cancer Therapies Amid Biopharma Sector Growth
20 Mar 24
Anixa Biosciences (NASDAQ:ANIX) Gains Attention for Its Innovative Cancer Therapies Amid Biopharma Sector Growth
20 Mar 24